Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Cohort Study of Surufatinib With or Without Immunotherapy in Patients With Advanced Colorectal Cancer Who Have Failed Front-line Antiangiogenic TKI Therapy

Next Previous
Trial Profile

A Single-center, Open-label, Cohort Study of Surufatinib With or Without Immunotherapy in Patients With Advanced Colorectal Cancer Who Have Failed Front-line Antiangiogenic TKI Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Surufatinib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 Nov 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 30 to 50, treatment arm changed from 1 to 2. Study design changed from Single Group Assignment to Parallel Assignment.
  • 05 Nov 2022 Planned number of patients changed from 30 to 50.
  • 05 Nov 2022 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top